Primary Results from a Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma
Roshani Patel, Elizabeth Hill(University of Maryland, Baltimore), Mark Roschewski(National Cancer Institute), Dickran Kazandjian(United States Food and Drug Administration), Max J. Gordon(Oregon Health & Science University), Raul C. Braylan(Center for Cancer Research), Liza Lindenberg(National Cancer Institute), Ryan M. Young(Denver Health Medical Center), Amrit Bhaskarla, Hao‐Wei Wang(Fu Jen Catholic University), M. John Esther, Irina Marić(Center for Cancer Research), Michael Emanuel(National Institutes of Health), Constance M. Yuan(National Cancer Institute), Calvo Kathy, Barış Türkbey(National Institutes of Health)
Cited by 0
Related Papers
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Oncogenically active MYD88 mutations in human lymphoma
|Nature|2010|1.5k
A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications
|Cancer Cell|2020|1.1k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k